M. Arning
67 works · 8,390 citations · h-index 29
Top works
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura
- A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
- Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
- Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium
- Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study
- Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer
- A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy
- A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer
- Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia
- Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
- Infusion‐related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels
- Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial.
- A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639–1645
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, with Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients with Bladder Cancer
- Phase I trial of gemcitabine (Gemzar®), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
- Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer
- A Report on Serious Pulmonary Toxicity Associated with Gemcitabine-Based Therapy